February 9, 2009

Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735

Does four cycles of docetaxel with cyclophosphamide improve overall survival and disease-free survival compared to doxorubicin and cyclophosphamide?

P

Population

Older and younger patients

I

Intervention

Four cycles of TC (docetaxel with cyclophosphamide)

C

Comparator

Standard AC (doxorubicin and cyclophosphamide)

O

Outcome

Overall survival (OS) and disease-free survival (DFS)hard clinical

At 7-year follow-up, docetaxel with cyclophosphamide provides a survival benefit over standard doxorubicin and cyclophosphamide.

With longer follow-up, four cycles of TC was superior to standard AC (DFS and OS) and was a tolerable regimen in both older and younger patients.

Cite This Study